Please assess the completion status of the following clinical trial:

Trial Title: Effect of a Fibrate and a Statin on Endothelial Dysfunction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age greater than 30 years~* Adult-onset DM (defined as fasting glucose greater than 125 mg/dl or by ongoing treatment with an oral hypoglycemic agent) or metabolic syndrome (defined as at least 3 of the following: 1. HDL less than 40 mg/dl for men or less than 50 mg/dl for women; 2. triglycerides greater than 150 mg/dl; 3. waist circumference greater than 40 inches for men and greater than 35 inches for women; 4. fasting glucose greater than 100 mg/dl).~* LDL cholesterol level less than 140 mg/dl~* Able to provide informed consent and complete study procedures~Exclusion Criteria:~* Change in therapy for glucose control or blood pressure less than 1 month before entry~* Hemoglobin A1C greater than 8.0%.~* Renal insufficiency (serum creatinine greater than 1.6 mg/dl in men or 1.5 mg/dl in women.~* Any investigational drug less than 1 month before entry.~* Pregnancy (excluded by urine pregnancy test at study entry with ongoing use of reliable form of birth control) or lactation~* Liver function tests or serum creatinine kinase (CK) greater than 3 times upper limit of normal.~* Clinically evident major illnesses or other problem that would make participation inappropriate~* Clinical history of symptomatic cholelithiasis~* Patients with coronary artery disease, peripheral arterial disease, or cerebral vascular disease will not be enrolled if they are currently taking lipid-lowering therapy~* Patients taking more than 40 mg/day of atorvastatin will be excluded. There is no ceiling level for patients taking fibrates.

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fenofibrate First (Type: ACTIVE_COMPARATOR): Fenofibrate 145 mg/day for 8 weeks First and Atorvastatin 20 mg/day for 8 weeks Second
- Atorvastatin First (Type: ACTIVE_COMPARATOR): Atorvastatin 20 mg/day for 8 weeks First and Fenofibrate 145 mg/day for 8 weeks Second

Based on this trial design, predict the completion outcome and termination type (if applicable).